In a recent conversation, Howie and Harlan were joined by Atheendar Venkataramani, a physician, health economist, and director of the Perelman School of Medicine’s Opportunity for Health Lab. They discussed the powerful role of economic opportunity in population health outcomes.
Howie reflected on the business model of the pharmaceutical industry and the market reaction to anti-obesity drugs, while Harlan reported on two studies where treatments’ unexpected benefits leapt ahead of understanding why they work. They also talked about the impact of college affirmative action bans on smoking and alcohol use among underrepresented minority adolescents in the United States, as well as the spillover effects of police killings on the mental health of black Americans.
The conversation also covered specific medical treatments and trials, such as the use of Semaglutide in patients with obesity-related heart failure and type 2 diabetes, the coronary sinus reducer for refractory angina treatment, and a placebo-controlled trial for PCI for stable angina. Additionally, they discussed the potential for biotech stocks and companies like Eli Lilly’s growth potential.
Those interested in learning more about business and healthcare topics are encouraged to check out Yale SOM’s MBA for Executives program. Readers can email Howie and Harlan with any comments or questions they may have.
